Skip to main content


Page 10 of 14

  1. The contact system, also named as plasma kallikrein-kinin system, consists of three serine proteinases: coagulation factors XII (FXII) and XI (FXI), and plasma prekallikrein (PK), and the nonenzymatic cofactor...

    Authors: Yi Wu
    Citation: Thrombosis Journal 2015 13:17
  2. Systemic Lupus Erythematosus (SLE) is an acquired, multiorgan, autoimmune disease. Clinical presentation is extremely variable and heterogeneous. It has been shown that SLE itself is an independent risk factor...

    Authors: Mario Bazzan, Antonella Vaccarino and Fabio Marletto
    Citation: Thrombosis Journal 2015 13:16
  3. In recent years, the relationship between inflammation and thrombosis has been deeply investigated and it is now clear that immune and coagulation systems are functionally interconnected.

    Authors: Giacomo Emmi, Elena Silvestri, Danilo Squatrito, Amedeo Amedei, Elena Niccolai, Mario Milco D’Elios, Chiara Della Bella, Alessia Grassi, Matteo Becatti, Claudia Fiorillo, Lorenzo Emmi, Augusto Vaglio and Domenico Prisco
    Citation: Thrombosis Journal 2015 13:15
  4. Inflammatory bowel disease affects more than 2 million people in Europe, with almost 20% of patients being diagnosed in pediatric age. Patients with inflammatory bowel disease are at increased risk of thromboe...

    Authors: Martina Giannotta, Gherardo Tapete, Giacomo Emmi, Elena Silvestri and Monica Milla
    Citation: Thrombosis Journal 2015 13:14
  5. Deep vein thrombosis (DVT) is a common disease and is associated with pulmonary embolism (PE). Proximal iliofemoral DVT may lead to severe PE and chronic venous insufficiency. The standard therapy for DVT is a...

    Authors: Norimichi Koitabashi, Nogiku Niwamae, Tetsuya Taguchi, Yoshiaki Ohyama, Noriaki Takama and Masahiko Kurabayashi
    Citation: Thrombosis Journal 2015 13:13
  6. Obesity is currently regarded as a pro-inflammatory condition during which leptin (Ob gene product) might act as a risk factor for Cardiovascular Diseases (CVD) including Acute Myocardial Infarction (AMI). There ...

    Authors: Devarajan Nalini, Rajendran Karthick, Vijay Shirin, Ganesan Manohar and Raghunathan Malathi
    Citation: Thrombosis Journal 2015 13:12
  7. The Editors of Thrombosis Journal would like to thank all of our reviewers who have contributed to the journal in Volume 12 (2014) and whose valuable support is fundamental to its success.

    Authors: Yukio Ozaki and Hugo ten Cate
    Citation: Thrombosis Journal 2015 13:11
  8. Current clinical practice guidelines recommend the use of prophylactic doses of low molecular weight heparins for cancer patients requiring hospitalization for acute medical illness. However, a recently publis...

    Authors: Patricia Moretto, Junghyun Park, Marc Rodger, Grégoire Le Gal and Marc Carrier
    Citation: Thrombosis Journal 2015 13:10
  9. Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the prin...

    Authors: Herm Jan M Brinkman
    Citation: Thrombosis Journal 2015 13:9
  10. Behçet’s disease (BD) is a rare vasculitis in sub-Saharan Africa. Vascular thrombosis, especially venous, is common in this condition and also constitutes a basic diagnostic criterion. Its affection of the sup...

    Authors: Simon Antoine Sarr, Pape Diadie Fall, Mouhamadou Chérif Mboup, Khadidiatou Dia, Malick Bodian and Modou Jobe
    Citation: Thrombosis Journal 2015 13:7
  11. Edoxaban is an oral, direct, factor Xa inhibitor approved in Japan for thromboembolic prophylaxis after lower-limb orthopedic surgery (LLOS), but contraindicated in patients with severe renal impairment (SRI; ...

    Authors: Takeshi Fuji, Satoru Fujita, Yohko Kawai, Yasuyuki Abe, Tetsuya Kimura, Masayuki Fukuzawa, Kenji Abe and Shintaro Tachibana
    Citation: Thrombosis Journal 2015 13:6
  12. Ideal conditions for platelet reactivity testing are critical for optimal selection of a P2Y12 inhibitor. Data are inconsistent regarding the impact of high-fat meals on test assessment.

    Authors: Paul P Dobesh, Jamela F Urban, Scott W Shurmur and Julie H Oestreich
    Citation: Thrombosis Journal 2015 13:3
  13. The global EINSTEIN DVT and PE studies compared rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K antagonist therapy and demonstrated non-inferiority for effica...

    Authors: Norikazu Yamada, Atsushi Hirayama, Hideaki Maeda, Satoru Sakagami, Hiroo Shikata, Martin H Prins, Anthonie WA Lensing, Masaharu Kato, Junichi Onuma, Yuki Miyamoto, Kazuma Iekushi and Mariko Kajikawa
    Citation: Thrombosis Journal 2015 13:2

    The Erratum to this article has been published in Thrombosis Journal 2016 14:11

  14. Homocysteine is an amino acid that is toxic to vascular endothelial cells, and plasma elevations have been associated with venous thromboembolism. Severe hyperhomocysteinemia (>100 μmol/L) may result from muta...

    Authors: Zuhier Awan, Sumayah Aljenedil, David S Rosenblatt, Jean Cusson, Brian M Gilfix and Jacques Genest
    Citation: Thrombosis Journal 2014 12:30
  15. Mild therapeutic hypothermia is considered standard care in the treatment of patients resuscitated from cardiac arrest. With increasingly more frequent concomitant use of platelet-inhibiting drugs, clinicians ...

    Authors: Sven Van Poucke, Kris Stevens, Abraham Emanuel Marcus and Marcus Lancé
    Citation: Thrombosis Journal 2014 12:31
  16. In clinical trials new oral anticoagulants (NOAC) have proved to be as effective as warfarin for thromboprophylaxis in atrial fibrillation. The aim of this study was to evaluate the efficacy and safety of thes...

    Authors: Ashkan Labaf, Martin Carlwe and Peter J Svensson
    Citation: Thrombosis Journal 2014 12:29
  17. Venous thromboembolism (VTE) requires urgent diagnosis and treatment to avoid related complications. Clinical presentations of VTE are nonspecific and require definitive confirmation by imaging techniques. A c...

    Authors: Tarek Owaidah, Nahlah AlGhasham, Saad AlGhamdi, Dania AlKhafaji, Bandar ALAmro, Mohamed Zeitouni, Fawaz Skaff, Hazzaa AlZahrani, Adher AlSayed, Naser ElKum, Mahmoud Moawad, Ahmed Nasmi, Mohannad Hawari and Khalid Maghrabi
    Citation: Thrombosis Journal 2014 12:28
  18. Statins may reduce the risk of first and recurrent venous thromboembolism (VTE). No data are available on their potential benefit in patients treated with the oral anticoagulant rivaroxaban.

    Authors: Philip S Wells, Martin Gebel, Martin H Prins, Bruce L Davidson and Anthonie WA Lensing
    Citation: Thrombosis Journal 2014 12:26
  19. Patients with renal impairment receiving classical anticoagulation for venous thromboembolism (VTE) are at increased risk of bleeding and possibly pulmonary embolism. We examined the efficacy and safety of ora...

    Authors: Rupert M Bauersachs, Anthonie WA Lensing, Martin H Prins, Dagmar Kubitza, Ákos F Pap, Hervé Decousus, Jan Beyer-Westendorf and Paolo Prandoni
    Citation: Thrombosis Journal 2014 12:25
  20. Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment...

    Authors: Jonathan Douxfils, Anne Tamigniau, Bernard Chatelain, Catherine Goffinet, Jean-Michel Dogné and François Mullier
    Citation: Thrombosis Journal 2014 12:24
  21. Increasing age and renal impairment are risk factors for venous thrombosis but also for anticoagulant-induced bleeding. In large-scale phase III trials, non-VKA oral anticoagulants (NOACs) were at least as eff...

    Authors: Vincent Geldhof, Christophe Vandenbriele, Peter Verhamme and Thomas Vanassche
    Citation: Thrombosis Journal 2014 12:21
  22. Warfarin is known for its interaction with many drugs, resulting in undesired treatment outcomes such as bleeding. The study aimed to assess the prevalence of drug-drug interactions and determinants of bleedin...

    Authors: Gebrehiwot Teklay, Nuredin Shiferaw, Befikadu Legesse and Mebratu Legesse Bekele
    Citation: Thrombosis Journal 2014 12:20
  23. Enoxaparin displays fibrinolytic activity through stimulation of endothelial release of tissue plasminogen activator. Moreover, enoxaparin increases the release of tissue factor pathway inhibitor, which inhibi...

    Authors: Gesa Wiegand, Vanya Icheva, Martin Schöning and Michael Hofbeck
    Citation: Thrombosis Journal 2014 12:19
  24. Erythropoietin (Epo) has been shown to improve myocardial function in models of experimental myocardial infarction, but has also been associated with a rise in thromboembolic events. Thus, the aim of this stud...

    Authors: Gabriele Demetz, Magdalena Laux, Armin Scherhag, Tiny Hoekstra, Marit M Suttorp, Friedo Dekker, Mark Roest, Mira Marcus-Kalish, Moshe Mittelman and Ilka Ott
    Citation: Thrombosis Journal 2014 12:18
  25. To evaluate the association between angiotensin I-converting enzyme insertion/deletion (ACE I/D) gene polymorphism and retinal vein occlusion (RVO). A total of 80 patients with retinal vein occlusion who was a...

    Authors: Işıl Kutluturk, Ali Karagöz, Tahir Bezgin, Vecih Oduncu, Ali Elveran, Cem Doğan, Ahmet Elbay, Cevat Kirma and Yusuf Özertürk
    Citation: Thrombosis Journal 2014 12:17
  26. Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related diseases remains high. Anticoagulati...

    Authors: Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Verena Haupt, Jonas Schneider and Alexander GG Turpie
    Citation: Thrombosis Journal 2014 12:16
  27. Venous thromboembolic disease (VTE) is associated with high morbi-mortality. Adherence rate to the recommendations of antithrombotic prophylaxis guidelines (ATPG) is suboptimal. The aim of this study was to de...

    Authors: Fernando Vazquez, Ricardo Watman, Aldo Tabares, Carina Gumpel, Enrique Baldessari, Alicia B Vilaseca, Federico J Capparelli and Esteban Lifschitz
    Citation: Thrombosis Journal 2014 12:15
  28. Atrial fibrillation (AF) patients frequently require anticoagulation with vitamin K antagonists (VKAs) to prevent thromboembolic events, but their use increases the risk of hemorrhage. We evaluated time spent ...

    Authors: Elizabeth S Mearns, C Michael White, Christine G Kohn, Jessica Hawthorne, Ju-Sung Song, Joy Meng, Jeff R Schein, Monika K Raut and Craig I Coleman
    Citation: Thrombosis Journal 2014 12:14
  29. Atrial fibrillation (AF) is a common cardiac arrhythmia, and leading cause of ischemic stroke. Despite proven effectiveness, warfarin remains an under-used treatment in atrial fibrillation patients. We sought ...

    Authors: Stuart G Nicholls, Jamie C Brehaut, Rubab G Arim, Kelly Carroll, Richard Perez, Kaveh G Shojania, Jeremy M Grimshaw and Roy M Poses
    Citation: Thrombosis Journal 2014 12:13
  30. Deep venous thrombosis (DVT), which is often associated with pulmonary embolism (PE), is a serious complication after total knee arthroplasty (TKA). In the present study, we examined the overall thrombotic and...

    Authors: Yukinori Tamura, Shigeshi Mori, Shigeki Asada, Naoyuki Kawao, Shigeru Ueshima, Hiroshi Kaji, Junichiro Yamamoto, Masao Akagi and Osamu Matsuo
    Citation: Thrombosis Journal 2014 12:11
  31. Platelet inhibitors are commonly used to reduce the risk of atherothrombotic events. The aim of this study was to determine the impact of platelet inhibitors, specifically clopidogrel and aspirin, on clot kine...

    Authors: Joseph F Dwyer, Jill A McCoy, Ziping Yang, Michael Husser, Heinz Redl, Mary Ann Murphy, Martin Wolfsegger, James P DiOrio, Andreas Goppelt and Shane Donovan
    Citation: Thrombosis Journal 2014 12:10
  32. Venous thromboembolism (VTE) prophylaxis is underutilized for hospitalized patients. The primary objective of this study was to assess the impact of a continuing medical education (CME) program on thromboproph...

    Authors: Fahad Al-Hameed, Hasan M Al-Dorzi and Essam Aboelnazer
    Citation: Thrombosis Journal 2014 12:9
  33. New oral anticoagulant (NOAC) drugs are known to influence the results of some routine hemostasis tests. Further data are needed to enable routine assessment of the effects of NOAC on clotting parameters in so...

    Authors: Raul Altman and Claudio Daniel Gonzalez
    Citation: Thrombosis Journal 2014 12:7
  34. Thromboelastography® (TEG) utilizes kaolin, an intrinsic pathway activator, to assess clotting function. Recent published studies suggest that TEG results are commonly normal in patients receiving warfarin, de...

    Authors: C Michael Dunham, Charlene Rabel, Barbara M Hileman, Jason Schiraldi, Elisha A Chance, Mark T Shima, Alddo A Molinar and David A Hoffman
    Citation: Thrombosis Journal 2014 12:4
  35. The Editors of Thrombosis Journal would like to thank all our reviewers who have contributed to the journal in Volume 11 (2013).

    Authors: Yukio Ozaki and Hugo ten Cate
    Citation: Thrombosis Journal 2014 12:2
  36. Paxillin is a LIM domain protein localized at integrin-mediated focal adhesions. Although paxillin is thought to modulate the functions of integrins, little is known about the contribution of paxillin to signa...

    Authors: Asuka Sakata, Tsukasa Ohmori, Satoshi Nishimura, Hidenori Suzuki, Seiji Madoiwa, Jun Mimuro, Kazuomi Kario and Yoichi Sakata
    Citation: Thrombosis Journal 2014 12:1
  37. Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic stroke, and strokes due to AF have a higher mor...

    Authors: Christopher Ward, Greg Conner, Geoffrey Donnan, Alexander Gallus and Simon McRae
    Citation: Thrombosis Journal 2013 11:27
  38. Left atrial appendage (LAA) thrombosis is an important cause of cardiogenic cerebral thromboembolism. Apixaban is a member of the class of novel oral anticoagulants (NOAC) and is superior to warfarin in preven...

    Authors: Tohru Kawakami, Hiroko Kobayakawa, Hiroyoshi Ohno, Nobukiyo Tanaka and Hiroki Ishihara
    Citation: Thrombosis Journal 2013 11:26
  39. The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized 8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) and, for the first time in trials in this setting, i...

    Authors: Yuqi Wang, Chen Wang, Zhong Chen, Jiwei Zhang, Zhihong Liu, Bi Jin, Kejing Ying, Changwei Liu, Yuxia Shao, Zhicheng Jing, Isabelle Ling Meng, Martin H Prins, Ákos F Pap, Katharina Müller and Anthonie WA Lensing
    Citation: Thrombosis Journal 2013 11:25

Official journal of

  • Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.

    Members of APSTH are entitled to a 15% discount on the article processing charge.

Annual Journal Metrics